secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001437749-26-015928
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M
--------------------------------------------------------------------------------

- Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.
- Revenue $10.1M, down 27.3% from $13.9M; operating loss $1.1M vs $0.7M income.
- Nine-month net loss $1.5M ($0.05 loss per share) vs net income $1.0M ($0.03 EPS).
- Two largest customers in Contract Manufacturing segment represented 90% of nine-month revenue (83% prior year).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/0001437749-26-015928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/inbp20260507_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-015928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer